Anti–PD-1 Therapy for Patients with Advanced Cholangiocarcinoma: Ready for Prime Time?

Anti–PD-1 Therapy for Patients with Advanced Cholangiocarcinoma: Ready for Prime Time?

Saved in:

Bibliographic Details
Main Authors:	Gagandeep Brar, Rachna T. Shroff
Format:	Article
Language:	English
Published:	Innovative Healthcare Institute 2025-05-01
Series:	Journal of Immunotherapy and Precision Oncology
Online Access:	https://jipo.org/doi/pdf/10.36401/JIPO-25-X3
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?
by: Alexander Meisel
Published: (2019-12-01)

The Surprise Question: Not Ready for Prime Time
by: Mellar P. Davis
Published: (2024-10-01)

Commentary: Almost ready for prime timeCentral Message
by: Lawrence M. Wei, MD
Published: (2020-09-01)

Endoscopic 'Antireflux' Procedures: Not Yet Ready For Prime Time
by: Joseph Romagnuolo
Published: (2004-01-01)

Commentary: Interesting…maybe not ready for prime time?Central Message
by: Stephanie H. Chang, MD
Published: (2021-10-01)

Aldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?
by: Alessio Mazzieri, et al.
Published: (2024-01-01)

Utilization of exosome-based therapies to augment anti-PD-1/PD-L1 therapies
by: John S. Wang, et al.
Published: (2025-04-01)

ALBI Grade Analyses of TACE Combined with Anti-Angiogenesis Therapies Plus PD-1 Inhibitors versus Anti-Angiogenesis Therapies Plus PD-1 Inhibitors in Advanced HCC
by: Hong X, et al.
Published: (2024-12-01)

Assessing congestion using estimated plasma volume status: Ready for prime time?
by: Phuuwadith Wattanachayakul, et al.
Published: (2025-02-01)

Anti-PD-1 Therapy-Associated Perforating Colitis
by: Romulo Celli, et al.
Published: (2018-01-01)

Efficacy and safety outcomes of PD-1/PD-L1 inhibitors in recurrent cholangiocarcinoma: a real-world, multicenter and retrospective study
by: Lihui Lin, et al.
Published: (2025-07-01)

Prospective studies on decompressive craniotomy for malignant MCA infarctions in Brazil: ready for prime time
by: Lucas Scotta Cabral, et al.

Characterization of Immunogenicity of Malignant Cells with Stemness in Intrahepatic Cholangiocarcinoma by Single-Cell RNA Sequencing
by: Jing Bian, et al.
Published: (2022-01-01)

PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma
by: Michael B. Atkins, et al.
Published: (2021-10-01)

PHOTODYNAMIC THERAPY IN PATIENTS WITH HILAR CHOLANGIOCARCINOMA
by: L. I. Moskvicheva
Published: (2019-04-01)

Advances in PD-1 and PD-L1 inhibitors targeted therapies for NSCLC: Mechanisms, Biomarkers, Combination Therapies
by: Xiang Zhiyuan
Published: (2025-01-01)

Patient-derived colorectal microtumors predict response to anti-PD-1 therapy
by: Duy T. Nguyen, et al.
Published: (2025-08-01)

An exploration of the initiation time and patient selection of PD-1 inhibitors/PD-1 inhibitors combined with chemotherapy as salvage therapy in R/R DLBCL patients after anti-CD19-CAR T-cell therapy
by: Xin Li, et al.
Published: (2025-06-01)

Red Cell Distribution Width as a Biomarker for Heart Failure: Still Not Ready for Prime-Time
by: Sunil K Nadar, et al.
Published: (2019-11-01)

Therapy for hilar cholangiocarcinoma
by: D. Yu. Frantsev, et al.
Published: (2019-02-01)

Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study)
by: Naoki Takahashi, et al.
Published: (2024-11-01)

Efficacy and prognostic factors of anti-PD1 and nivolumab-ipilimumab therapy in advanced melanoma patients resistant to prior ICI treatment
by: Caner Acar, et al.
Published: (2024-12-01)

Perspectives of Targeting Autophagy as an Adjuvant to Anti-PD-1/PD-L1 Therapy for Colorectal Cancer Treatment
by: Nasrah ALKhemeiri, et al.
Published: (2025-05-01)

IL-18-primed NK cells recruit dendritic cells and potentiate tumor therapy mediated by PD-1 blockade
by: Yoshiya Ohno, et al.
Published: (2025-03-01)

A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
by: Diana I. Albu, et al.
Published: (2024-12-01)

Systemic therapy for advanced cholangiocarcinoma: divergences in global guidelines and regional clinical implementation
by: LI Chun, MA Zuyi, SUN Jia, LI Binglu
Published: (2025-03-01)

Residual Tumor Resection After Anti-PD-1 Therapy: A Promising Treatment Strategy for Overcoming Immune Evasive Phenotype Induced by Anti-PD-1 Therapy in Gastric Cancer
by: Hajime Matsuida, et al.
Published: (2025-08-01)

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
by: Santosh Kesari, et al.
Published: (2022-02-01)

Retrospective Analysis of Adoptive TIL Therapy plus Anti-PD1 Therapy in Patients with Chemotherapy-Resistant Metastatic Osteosarcoma
by: Xiang Zhou, et al.
Published: (2020-01-01)

PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy
by: Paul Nghiem, et al.
Published: (2020-10-01)

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1
by: Debayan Mukherjee, et al.
Published: (2023-12-01)

Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
by: Hongshu Sui, et al.
Published: (2018-01-01)

FMO2+ cancer-associated fibroblasts sensitize anti-PD-1 therapy in patients with hepatocellular carcinoma
by: Hui Li, et al.
Published: (2025-05-01)

Anti-PD-1 therapy for preventing recurrence and improving survival in hepatocellular carcinoma patients after hepatectomy
by: Xiansheng Zhao, et al.
Published: (2025-08-01)

Exploring correlations between gut mycobiome and lymphocytes in melanoma patients undergoing anti-PD-1 therapy
by: Natalia Szóstak, et al.
Published: (2025-02-01)

Targeted therapies and immunotherapies for unresectable cholangiocarcinoma
by: Shengbai Xue, et al.
Published: (2025-08-01)

Unsectable cholangiocarcinoma: Additional therapy to chemoradiotherapy
by: Kamon Chaiyasit, et al.
Published: (2013-01-01)

Are we ready to use anti-amyloid therapy in Alzheimer's disease?
by: Sonia Maria Dozzi Brucki, et al.
Published: (2022-08-01)

Identification of PD-L1-related biomarkers for selecting gastric adenocarcinoma patients for PD-1/PD-L1 inhibitor therapy
by: Bo-Ya Li, et al.
Published: (2025-05-01)

CD57+ EMRA CD8+ T cells in cancer patients over 70: associations with prior chemotherapy and response to anti-PD-1/PD-L1 therapy
by: Cécile Gonnin, et al.
Published: (2024-12-01)